arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

ROCKET PHARMACEUTICALS, INC.

RCKT
$2.44 ▼ -0.18 (-6.88%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
51 Visible periods
22 Metrics
Peer-ranked Benchmarks
Price Chart
20
Health
Poor
Bearish
auto_awesome

Analytical Summary

ROCKET PHARMACEUTICALS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $275.3M
Dividend Yield —
Revenue Growth —
Op. Margin —
ROIC -11.9% ↗
FCF / Share $-0.35 ↗
Trailing P/E 2.2x
Price / Book 0.7x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

51-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
— —
Net Income Profit after all expenses
$-47.59M
↑ +22.4% —
FCF / Share Free cash flow per share
$-0.35
↑ +13.4% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓
11
Financial Health ↓
12
Cash Quality ↑
57

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 13 years · 51 quarters